Long-term treatment with Tyvaso DPI safely and effectively leads to increases in exercise capacity in adults with pulmonary arterial hypertension (PAH). Tyvaso DPI is a dry powder, inhaled form of treprostinil. Patient satisfaction was also improved with Tyvaso DPI compared with Tyvaso, which is a nebulized, inhaled formulation…
News
A new sequential strategy successfully treats people with severe chronic thromboembolic pulmonary hypertension (CTEPH), significantly reducing high blood pressure and improving heart function, a study finds. The three-step regimen — medication, balloon pulmonary angioplasty (BPA), and pulmonary endarterectomy (PEA) surgery — is designed for people facing unacceptably high surgical…
A new experimental therapy for pulmonary arterial hypertension (PAH), called ALG-801, has shown superior efficacy over current standard-of-care treatments in early laboratory studies, according to its developer, Alivegen. In animal testing, the medication reduced signs of the disease by targeting a molecular pathway involved in the abnormal growth…
Worldwide, pulmonary arterial hypertension (PAH) affects more than 2 of every 100,000 females ages 15 to 49 — women and girls of childbearing age — according to a new analysis of data spanning some three decades. The researchers noted that the rates of PAH vary substantially in different parts…
The PAH Initiative is hosting video events in November to discuss the importance of shared decision making between doctors and patients to help manage pulmonary arterial hypertension (PAH). The hour-long broadcasts, which are intended for adults with PAH and their caregivers, will take place at 8 p.m. EST…
Winrevair (sotatercept-csrk), when added to standard of care, reduced clinical worsening events by 76% in adults recently diagnosed with pulmonary arterial hypertension (PAH). That’s according to now-published data from the Phase 3 HYPERION (NCT04811092) clinical trial, which evaluated …
Stem cell-derived conditioned medium, or the liquid that remains after cells are cultured, reduces the signs of pulmonary arterial hypertension (PAH) in rat and cell models, a study showed. “These findings support [stem cell]‐derived conditioned medium as a promising therapeutic strategy for PAH, warranting further investigation in translational studies…
Gossamer Bio is moving toward acquiring Respira Therapeutics and its lead treatment candidate, RT234, an inhaled therapy being developed for the on-demand treatment of pulmonary hypertension (PH). The two companies entered into an option agreement that gives Gossamer the exclusive right to this acquisition within an agreed-upon…
For pregnant women with pulmonary hypertension (PH), higher pulmonary arterial pressure — blood pressure levels in the blood vessels that supply the lungs — is associated with longer hospital stays and a greater chance of being admitted to the intensive care unit (ICU). That’s according to a new study…
Underweight infants with pulmonary hypertension (PH) are at increased risk of developing retinopathy of prematurity (ROP), a leading cause of childhood blindness, according to a study. However, the prevalence of severe ROP was 18% lower in PH infants who received treatment with inhaled nitric oxide (iNO). “While iNO is…
The European Patent Office has given Tenax Therapeutics notice that it plans to grant a patent covering the use of levosimendan and its active metabolites to treat pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), the company said. TNX-103, an oral formulation currently in Phase…
Allrock Bio has raised $50 million in financing to support the clinical development of pulmonary hypertension (PH) treatment ROC-101. The company said it will use the funds to launch a Phase 2a clinical trial to test ROC-101 in people with pulmonary arterial hypertension (PAH) or pulmonary hypertension associated…
